In Focus channel feed

How a du­ty to spend wise­ly on work­er ben­e­fits could loosen PBM­s' grip on drug prices

5 months ago
Pharma
Law

In­side Iso­mor­phic Labs: Demis Has­s­abis’ lab-free vi­sion for biotech’s AI fu­ture

6 months ago
AI

As 23andMe strug­gles, an­oth­er ge­net­ic test­ing com­pa­ny bets on drug dis­cov­ery

6 months ago
R&D
Discovery

Law­mak­ers are pok­ing holes in phar­ma's fa­vorite new way to mar­ket med­i­cines

6 months ago
Pharma
Health Tech

A rare neu­ro­log­i­cal dis­ease is Sage’s last, best hope af­ter fail­ures in de­pres­sion

6 months ago
R&D
Pharma

Yorvipath’s ap­proval show­cas­es bio­phar­ma’s in­ter­est in rare en­docrine dis­or­der

7 months ago
Startups
R&D

Biotech in­dus­try wor­ries over po­ten­tial for RFK Jr. al­ly as FDA pick

7 months ago
FDA+

Is there room for MASH drugs in a GLP-1 world?

7 months ago
R&D
Pharma

Bad trip: How cul­ture con­flict and a need for cash near­ly broke Lykos

8 months ago
People

Re­cur­sion nears ‘mo­ment of truth’ with first key da­ta, kick­ing off 18-month flur­ry of read­outs

9 months ago
R&D
AI

Once one of im­muno-on­col­o­gy's next great hopes, CD47 faces fi­nal shots on goal

9 months ago
R&D

The obe­si­ty drug race is be­ing fought on the man­u­fac­tur­ing floor as GLP-1 ri­vals make plans to catch lead­ers

10 months ago
Pharma
Manufacturing

A teenag­er faced con­stant seizures. Could a drug de­vel­oped just for him stop them?

11 months ago
R&D
Discovery

Lykos’ pain is oth­ers’ gain as psy­che­del­ic biotechs take notes from ad­comm vote

11 months ago
R&D

The End­points Slack in­ter­view: Saji Wick­ra­masekara on where AI miss­es the mark — and what's next for Bench­ling

11 months ago
AI
Health Tech

How two aca­d­e­m­ic chemists turned San Diego start­up Iambic in­to an AI force

11 months ago
AI

BIO's new CEO takes a pa­tri­ot­ic piv­ot to win back Con­gress, push­ing in­dus­try to re­think Chi­na re­la­tion­ship

Last year
China

The End­points Slack in­ter­view: Sid­dhartha Mukher­jee on the doc­tor-writer world­view, AI, and the fu­ture of can­cer

Last year
R&D
AI

Af­ter CRISPR ba­by scan­dal shut down work for years, Chi­na gene edit­ing com­pa­nies are restart­ing clin­i­cal tri­als

Last year
China
Cell/Gene Tx

Ver­tex, Alpine’s IgAN drug has Hu­mi­ra-like po­ten­tial. But not all in­di­ca­tions are cre­at­ed equal

Last year
R&D

Cash, chips and tal­ent: In­side Nvidi­a's plan to dom­i­nate biotech's AI rev­o­lu­tion

Last year
R&D
AI

With GIP, obe­si­ty re­search is at odds

Last year
R&D

The US could up­end bio­phar­ma man­u­fac­tur­ing. WuXi ri­vals have an open­ing

Last year
China
Manufacturing

Fe­male in­vestors track progress, call for more women on boards and in lead­er­ship roles

Last year
People
Financing
First page Previous page 12345 Next page Last page
A service from the Financial Times